百利天恒(688506) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects to achieve an operating revenue of approximately 5,800 million yuan in 2024, an increase of about 932.27% compared to the previous year[4]. - The net profit attributable to the parent company is projected to be around 3,600 million yuan, marking a turnaround from a loss of 780.5 million yuan in the previous year[4][6]. - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is estimated to be approximately 3,555 million yuan, also a significant increase from a loss of 812.7 million yuan last year[4][6]. - The previous year's operating revenue was 561.87 million yuan, with a total profit of -769.01 million yuan[6]. Revenue Sources - The substantial increase in revenue is primarily due to an irrevocable and non-deductible upfront payment of 800 million USD received from Bristol-Myers Squibb (BMS) for the core product BL-B01D1[8]. Cautionary Notes - The company emphasizes that the performance forecast is based on preliminary calculations and has not been audited by certified public accountants[5][9]. - Investors are advised to consider the investment risks as the forecast data is subject to change pending the audited financial report[10].